Ventus Therapeutics Overview

  • Founded
  • 2019
  • Status
  • Private
  • Employees
  • 35
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $100M
Latest Deal Amount
  • Investors
  • 8

Ventus Therapeutics General Information


Developer of structural immunology-based therapeutics intended to navigate elusive targets. The company focuses on developing small-molecule medicines to target proteins in the inflammasome and nucleic acid-sensing signaling pathways, enabling medical practitioners to treat acute and chronic inflammatory and immune-related diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Primary Office
  • 7150 Rue Frédérick-Banting
  • Montreal, Quebec H4S 2A1
  • Canada
+1 (514) 000-0000

Ventus Therapeutics Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ventus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 08-Apr-2021 $100M 00000 Completed Generating Revenue
2. Early Stage VC (Series A) 06-May-2020 0000 0000 Completed Generating Revenue
1. Seed Round Completed Startup
To view Ventus Therapeutics’s complete valuation and funding history, request access »

Ventus Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Michael Crackower Ph.D Chief Scientific Officer
Daniel Koerwer Chief Business Officer
Feng Shao Ph.D Co-Founder
Judy Lieberman Ph.D Co-Founder
Thomas Tuschl Ph.D Co-Founder
You’re viewing 5 of 8 executive team members. Get the full list »

Ventus Therapeutics Board Members (8)

Name Representing Role Since
Brendan Bulik-Sullivan Ph.D GV Board Member 000 0000
Eli Casdin Casdin Capital Board Observer 000 0000
Hao Wu Ph.D Ventus Therapeutics Co-Founder & Board Member 000 0000
Jerel Davis Ph.D Versant Ventures Chairman 000 0000
Joshua Resnick MD RA Capital Management Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Ventus Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ventus Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
Casdin Capital Hedge Fund Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »